Search Results - "MARCUS, Robert E"

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study by VAN OERS, Marinus H. J, VAN GLABBEKE, Martine, HAGENBEEK, Anton, GIURGEA, Livia, KLASA, Richard, MARCUS, Robert E, WOLF, Max, KIMBY, Eva, VAN T VEER, Mars, VRANOVSKY, Andrej, HOLTE, Harald

“…In 2006, we published the results of the European Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in…”
Get full text

Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party by Montoto, Silvia, Corradini, Paolo, Dreyling, Martin, Ghielmini, Michele, Kimby, Eva, López-Guillermo, Armando, Mackinnon, Stephen, Marcus, Robert E, Salles, Gilles, Schouten, Harry C, Sureda, Anna, Dreger, Peter

“…The aim of this project was to define indications for hematopoietic stem cell transplantation in follicular lymphoma in Europe. In the absence of…”
Get full text

BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study by VAN OERS, Marinus H. J, TÖNNISSEN, Evelyn, HOLTE, Harald, HAGENBEEK, Anton, VAN DER REIJDEN, Bert A, VAN GLABBEKE, Martine, GIURGEA, Livia, JANSEN, Joop H, KLASA, Richard, MARCUS, Robert E, WOLF, Max, KIMBY, Eva, VRANOVSKY, Andrej

“…The prognostic value of residual BCL2/immunoglobulin heavy chain (BCL2/IgH) -positive cells in peripheral blood (PB) or bone marrow (BM) after induction…”
Get full text

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety by Hiddemann, Wolfgang, Barbui, Anna Maria, Canales, Miguel A, Cannell, Paul K, Collins, Graham P, Dürig, Jan, Forstpointner, Roswitha, Herold, Michael, Hertzberg, Mark, Klanova, Magdalena, Radford, John, Seymour, John F, Tobinai, Kensei, Trotman, Judith, Burciu, Alis, Fingerle-Rowson, Günter, Wolbers, Marcel, Nielsen, Tina, Marcus, Robert E

“…Purpose The GALLIUM study ( ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival…”
Get full text

Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long‐term follow‐up of a prospective study by Gandhi, Maher K., Lekamwasam, Sarath, Inman, Ingrid, Kaptoge, Stephen, Sizer, Lorraine, Love, Shirley, Bearcroft, Philip W., Milligan, Thomas P., Price, Christopher P., Marcus, Robert E., Compston, Juliet E.

“…Reduced bone mineral density (BMD) has been reported following allogeneic stem cell transplantation (alloSCT) but the effects of autologous SCT (autoSCT) are…”
Get full text

HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era by COUTINHO, Rita, PRIA, Alessia D, BURNS, Fiona, MARCUS, Robert E, ORKIN, Chloe, MONTOTO, Silvia, BOWER, Mark, GANDHI, Shreyans, BAILEY, Katharine, FIELDS, Paul, CWYNARSKI, Kate, WILSON, Andrew, PAPANASTASOPOULOS, Panagiotis, TENANT-FLOWERS, Melinda, WEBB, Andrew

“…To compare the outcome of patients diagnosed with HIV infection and diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP in the cART era with that of a…”
Get full text

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial by van Oers, Marinus H.J., Klasa, Richard, Marcus, Robert E., Wolf, Max, Kimby, Eva, Gascoyne, Randy D., Jack, Andrew, van't Veer, Mars, Vranovsky, Andrej, Holte, Harald, van Glabbeke, Martine, Teodorovic, Ivana, Rozewicz, Cynthia, Hagenbeek, Anton

“…We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). A total of 465…”
Get full text

Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study by Casulo, Carla, Herold, Michael, Hiddemann, Wolfgang, Iyengar, Sunil, Marcus, Robert E., Seymour, John F., Launonen, Aino, Knapp, Andrea, Nielsen, Tina G., Mir, Farheen

“…Although advanced‑stage follicular lymphoma (FL) is considered incurable, survival has improved with the introduction of the anti-CD20 antibodies, rituximab…”
Get full text

Haematopoietic stem cell transplantation does not retard disease progression in the psycho-cognitive variant of late-onset metachromatic leukodystrophy by Smith, Nicholas J., Marcus, Robert E., Sahakian, Barbara J., Kapur, Narinder, Cox, Timothy M.

“…Haematopoietic stem cell transplantation has an unproven role in the management of late-onset metachromatic leukodystrophy: theoretically justified through the…”
Get full text

Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation by TAYLOR, Anna L, BOWLES, Kristian M, CALLAGHAN, Christopher J, WIMPERIS, Jenny Z, GRANT, John W, MARCUS, Robert E, BRADLEY, J. Andrew

“…Recommended first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is reduction in immunosuppressive therapy, irrespective of…”
Get full text

Follicular lymphoma: time for a re-think? by Gandhi, Maher K., Marcus, Robert E.

“…Follicular lymphoma (FL) is a malignancy of follicle centre B cells that have at least a partially follicular pattern, and is the commonest type of indolent…”
Get full text

Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation by Gandhi, Maher K., Wills, Mark R., Okecha, Georgina, Day, Elizabeth K., Hicks, Ray, Marcus, Robert E., Sissons, J. G. Patrick, Carmichael, Andrew J.

“…To investigate the mechanisms of human T-cell reconstitution following allogeneic hemopoietic stem cell transplantation (alloSCT), we analyzed the clonal…”
Get full text

Invasive fungal sinusitis in patients treated with fludarabine by Todd, Tony, Besser, Martin, Gudgin, Emma, Crawley, Charles, Craig, Jenny I.O, Follows, George, Marcus, Robert E, Enoch, David A, Cargill, James S, Ludlam, Hugo A, Young Min, Sandra, Sartori, Pat

Get full text

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial by Barrington, Sally F, Belada, David, Meignan, Michel, Ptáčník, Václav, Fingerle-Rowson, Günter R, Hiddemann, Wolfgang, Marcus, Robert E, Grigg, Andrew, Quach, Hang, Marlton, Paula, Offner, Fritz, Van eygen, Koen, Roitman, Daryl, Trneny, Marek, Le Du, Katell, Solal-Celigny, Philippe, Cartron, Guillaume, Foussard, Charles, Schmidt, Peter, Sökler, Martin, Schimmelpfennig, Christoph, Tonndorf, Solveig, Hänel, Mathias, Hess, Georg, Schalk, Enrico, Pfreundschuh, Michael, Herold, Michael, Forstpointner, Roswitha, Vehling-Kaiser, Ursula, Majolino, Ignazio, Balzarotti, Monica, Soler Campos, Alfonso, Marquez Navarro, Jose Antonio, Grande Garcia, Carlos, Nilsson-Ehle, Herman, Radford, John, Kruger, Anton, Culligan, Dominic, Dyer, Martin, Pettengell, Ruth, Al-Ismail, Saad, Al-Refaie, Faris, Blesing, Norbert, Macnamara, Christopher, O'callaghan, Ann, Haynes, Andrew, Bowles, Kristian, Gallop-Evans, Eve, Bailey, James, De Oliveira, Moacyr, Tezcan, Haluk, Kim, Kevin, Hatake, Kiyohiko, Ogura, Michinori, Uchida, Toshiki, Kinoshita, Tomohiro, Kirsch, Andreas, Koenigsmann, Michael, Dürig, Jan, Kneba, Michael, Bergmann, Lothar, Marks, Reinhard, Wulf, Gerald, Schmits, Rudolf, Lengfelder, Eva, Scott, Fiona, Taniwaki, Masafumi, Yoshida, Isao, Uike, Naokuni, Kamitsuji, Yuri, Iida, Shinsuke, Ohmine, Ken, Nosaka, Kisato, Ide, Kazuhiko, Ishikawa, Takayuki, Li, Wei, Yu, Li, Shi, Yuan Kai, Hong, Xiaonan, Feng, Jifeng, Zhan, Rong, Lin, Tongyu, Costello, Regis, Tournilhac, Olivier, Kirchen, Heinz, Hebart, Holger, Gurion, Ronit, Shpilberg, Ofer, Leoni, Pietro, Samoylova, Olga, Usui, Noriko, Izutsu, Koji, Ichinohe, Tatsuo, Kubo, Kohmei, Ishida, Fumihiro, Dakhil, Shaker, Maruyama, Dai, Kobayashi, Tsutomu, Wada, Katsuya, Minami, Yosuke

“…Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line…”
Get full text

Autoimmune hemolytic anemia: magnetic resonance findings by Wat, Shiu Yan Josephine, Groves, Ashley M., Marcus, Robert E., Lomas, David J.

“…Idiopathic autoimmune hemolytic anemia (AIHA) is a rare hematological disease typically characterized by extracellular hemolysis. An unusual case of AIHA with…”
Get full text

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study by Casulo, Carla, Herold, Michael, Hiddemann, Wolfgang, Iyengar, Sunil, Marcus, Robert E., Seymour, John F., Launonen, Aino, Knapp, Andrea, Nielsen, Tina G, Mir, Farheen

“…Introduction: Predicting the risk of histologic transformation (HT) from indolent follicular lymphoma (FL) to a more aggressive form of lymphoma represents a…”
Get full text

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy by Jurinovic, Vindi, Passerini, Verena, Oestergaard, Mikkel Z, Knapp, Andrea, Mundt, Kirsten, Araf, Shamzah, Richter, Julia, Fitzgibbon, Jude, Klapper, Wolfram, Marcus, Robert E., Davies, Andrew, Herold, Michael, Hiddemann, Wolfgang, Unterhalt, Michael, Hoster, Eva, Weigert, Oliver

“…Introduction: We have previously shown that a clinicogenetic risk model called the m7- Follicular Lymphoma (FL) International Prognostic Index (m7-FLIPI),…”
Get full text

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study by Pott, Christiane, Hoster, Eva, Kehden, Britta, Unterhalt, Michael, Herold, Michael, van der Jagt, Richard H, Janssens, Ann, Kneba, Michael, Mayer, Jiri, Pocock, Chris, Danesi, Nathalie, Fingerle-Rowson, Günter, Harbron, Chris, Mundt, Kirsten, Marcus, Robert E, Hiddemann, Wolfgang

“…Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy in patients (pts) with…”
Get full text

Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population by Khan, Anjum Bashir, Hunt, Alesia Abigael, Potter, Victoria T, Kassam, Shireen, Yallop, Deborah, Patten, Piers E.M., Devereux, Stephen, Mufti, Ghulam, Pagliuca, Antonio, Marcus, Robert E.

“…Despite recent advances in care, central nervous system (CNS) lymphoma remains a disease with very poor long-term outcomes. We reviewed outcomes at our centre…”
Get full text

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study by Marcus, Robert E, Davies, Andrew J, Ando, Kiyoshi, Klapper, Wolfram, Opat, Stephen, Owen, Carolyn J, Phillips, Elizabeth H, Sangha, Randeep, Schlag, Rudolf, Seymour, John F, Townsend, William, Trněný, Marek, Wenger, Michael K, Fingerle-Rowson, Günter, Rufibach, Kaspar, Moore, Tom, Herold, Michael, Hiddemann, Wolfgang

“…▪ Background: Immunochemotherapy induction followed by maintenance with rituximab (R) is the standard of care (SoC) for pts with advanced-stage symptomatic…”
Get full text